Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults.

In a randomized, double-blinded study, 77 elderly seropositive volunteers were immunized with either liposome-adjuvanted or control subvirion vaccine containing 15 micrograms/dose of haemagglutinin from influenza A/Taiwan/1/86 (H1N1) virus. The liposome vaccine was well-tolerated but elicited serologic responses that were no different in frequency or magnitude from those induced by the control vaccine. Less than 20% of subjects in either group mounted a 4-fold or greater rise in antibody titer. Peripheral blood anti-influenza A cytotoxic T lymphocyte activity was enhanced to a greater extent by the liposome vaccine than by the control subvirion vaccine. It remains unclear whether liposome-adjuvanted formulations would have an advantage over conventional influenza vaccines for routine annual reimmunization of targeted high-risk populations.

RCT Entities:   Population Interventions Outcomes